BACKGROUND AND OBJECTIVES: Hypertension in older kidney donor candidates is viewed as safe. However, hypertension guidelines have evolved and long-term outcomes have not been explored. We sought to quantify the 15-year risk of ESKD and mortality in older donors (≥50 years old) with versus those without hypertension. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A United States cohort of 24,533 older donors from 1999 to 2016, including 2265 with predonation hypertension, were linked to Centers for Medicare and Medicaid Services data and the Social Security Death Master File to ascertain ESKD development and mortality. The exposure of interest was predonation hypertension. From 2004 to 2016, hypertension was defined as documented predonation use of antihypertensive therapy, regardless of systolic BP or diastolic BP; from 1999 to 2003, when there was no documentation of antihypertensive therapy, hypertension was defined as predonation systolic BP ≥140 or diastolic BP ≥90 mm Hg. RESULTS: Older donors were 82% white, 6% black, 7% Hispanic, and 3% Asian. The median follow-up was 7.1 years (interquartile range, 3.4-11.1; maximum, 18). There were 24 ESKD and 252 death events during the study period. The 15-year risk of ESKD was 0.8% (95% confidence interval [95% CI], 0.4 to 1.6) for donors with hypertension (mean systolic BP, 138 mm Hg) versus 0.2% (95% CI, 0.1 to 0.4) for donors without hypertension (mean systolic BP, 123 mm Hg; adjusted hazard ratio, 3.04; 95% CI, 1.28 to 7.22; P=0.01). When predonation antihypertensive therapy was available, the risk of ESKD was 6.21-fold higher (95% CI, 1.20 to 32.17; P=0.03) for donors using antihypertensive therapy (mean systolic BP, 132 mm Hg) versus those not using antihypertensive therapy (mean systolic BP, 124 mm Hg). There was no significant association between donor hypertension and 15-year mortality (hazard ratio, 1.18; 95% CI, 0.84 to 1.66; P=0.34). CONCLUSIONS: Compared with older donors without hypertension, older donors with hypertension had higher risk of ESKD, but not mortality, for 15 years postdonation. However, the absolute risk of ESKD was small.
BACKGROUND AND OBJECTIVES:Hypertension in older kidney donor candidates is viewed as safe. However, hypertension guidelines have evolved and long-term outcomes have not been explored. We sought to quantify the 15-year risk of ESKD and mortality in older donors (≥50 years old) with versus those without hypertension. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A United States cohort of 24,533 older donors from 1999 to 2016, including 2265 with predonation hypertension, were linked to Centers for Medicare and Medicaid Services data and the Social Security Death Master File to ascertain ESKD development and mortality. The exposure of interest was predonation hypertension. From 2004 to 2016, hypertension was defined as documented predonation use of antihypertensive therapy, regardless of systolic BP or diastolic BP; from 1999 to 2003, when there was no documentation of antihypertensive therapy, hypertension was defined as predonation systolic BP ≥140 or diastolic BP ≥90 mm Hg. RESULTS: Older donors were 82% white, 6% black, 7% Hispanic, and 3% Asian. The median follow-up was 7.1 years (interquartile range, 3.4-11.1; maximum, 18). There were 24 ESKD and 252 death events during the study period. The 15-year risk of ESKD was 0.8% (95% confidence interval [95% CI], 0.4 to 1.6) for donors with hypertension (mean systolic BP, 138 mm Hg) versus 0.2% (95% CI, 0.1 to 0.4) for donors without hypertension (mean systolic BP, 123 mm Hg; adjusted hazard ratio, 3.04; 95% CI, 1.28 to 7.22; P=0.01). When predonation antihypertensive therapy was available, the risk of ESKD was 6.21-fold higher (95% CI, 1.20 to 32.17; P=0.03) for donors using antihypertensive therapy (mean systolic BP, 132 mm Hg) versus those not using antihypertensive therapy (mean systolic BP, 124 mm Hg). There was no significant association between donorhypertension and 15-year mortality (hazard ratio, 1.18; 95% CI, 0.84 to 1.66; P=0.34). CONCLUSIONS: Compared with older donors without hypertension, older donors with hypertension had higher risk of ESKD, but not mortality, for 15 years postdonation. However, the absolute risk of ESKD was small.
Authors: Neil Boudville; G V Ramesh Prasad; Greg Knoll; Norman Muirhead; Heather Thiessen-Philbrook; Robert C Yang; M Patricia Rosas-Arellano; Abdulrahman Housawi; Amit X Garg Journal: Ann Intern Med Date: 2006-08-01 Impact factor: 25.391
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Jagbir Gill; Suphamai Bunnapradist; Gabriel M Danovitch; David Gjertson; John S Gill; Michael Cecka Journal: Am J Kidney Dis Date: 2008-07-24 Impact factor: 8.860
Authors: Hassan N Ibrahim; Dina N Murad; Sean A Hebert; Horacio E Adrogue; Hana Nguyen; Duc T Nguyen; Arthur J Matas; Edward A Graviss Journal: J Am Soc Nephrol Date: 2021-10-21 Impact factor: 10.121
Authors: Hassan N Ibrahim; Sean A Hebert; Dina N Murad; Horacio E Adrogue; Duc T Nguyen; Edward A Graviss; Hana Nguyen; Arthur Matas Journal: Kidney Int Rep Date: 2021-03-03
Authors: Massini A Merzkani; Aidan Mullan; Aleksandar Denic; Matthew D'Costa; Ryan Iverson; Walter Kremers; Mariam P Alexander; Stephen C Textor; Sandra J Taler; Mark D Stegall; Joshua Augustine; Naim Issa; Andrew D Rule Journal: Clin Transplant Date: 2021-03-30 Impact factor: 3.456
Authors: Anjay Rastogi; Stanley Yuan; Farid Arman; Lewis Simon; Kelly Shaffer; Mohammad Kamgar; Niloofar Nobakht; Jonathan S Bromberg; Matthew R Weir Journal: Transplant Direct Date: 2019-09-19
Authors: Fawaz Al Ammary; Jennifer D Motter; Hannah C Sung; Krista L Lentine; Asif Sharfuddin; Vineeta Kumar; Anju Yadav; Mona D Doshi; Sarthak Virmani; Beatrice P Concepcion; Terry Grace; Carolyn N Sidoti; Muhammad Yahya Jan; Abimereki D Muzaale; Joshua Wolf Journal: Am J Transplant Date: 2022-05-31 Impact factor: 9.369
Authors: Fawaz Al Ammary; Yifan Yu; Alexander Ferzola; Jennifer D Motter; Allan B Massie; Sile Yu; Alvin G Thomas; Deidra C Crews; Dorry L Segev; Abimereki D Muzaale; Macey L Henderson Journal: Am J Transplant Date: 2020-07-17 Impact factor: 8.086